Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Product sales	$ 4,205	$ 2,749	$ 10,215	$ 2,749
Lease income	37	38	104	38
Total revenues	4,242	2,787	10,319	2,787
Costs and expenses:
Costs of revenues	1,828	2,648	7,556	2,648
Research and development	2,803	1,829	7,682	7,375
General and administrative	5,347	7,977	13,490	20,669
Selling and marketing	2,062	975	4,879	975
(Gain) loss on disposal of intangible assets	0	0	(450)	48
Impairment of intangible assets	0	0	1,537	0
Acquired in-process research and development	10,862	0	11,943	5,849
Total cost and expenses	22,902	13,429	46,637	37,564
Loss from operations	(18,660)	(10,642)	(36,318)	(34,777)
Non-operating income/(expense):
Interest income, net	432	414	775	783
Other income	20	0	47	0
Foreign exchange (losses) gains	(526)	719	(278)	1,269
Change in fair value of investment in equity securities	1,978	(160)	2,287	(355)
Net loss	(16,756)	(9,669)	(33,487)	(33,080)
Less: (loss)/income attributable to redeemable noncontrolling interest	(309)	(23)	(584)	53
Accretion to redeemable noncontrolling interest redemption value	506	245	1,185	406
Net loss attributable to CASI Pharmaceuticals, Inc.	$ (16,953)	$ (9,891)	$ (34,088)	$ (33,539)
Net loss per share (basic and diluted) (in dollars per share)	$ (0.14)	$ (0.10)	$ (0.32)	$ (0.35)
Weighted average number of common shares outstanding (basic and diluted)	117,940	95,891	105,922	95,753
Comprehensive loss:
Net loss	$ (16,756)	$ (9,669)	$ (33,487)	$ (33,080)
Foreign currency translation adjustment	2,383	(1,836)	1,221	(2,636)
Total comprehensive loss	(14,373)	(11,505)	(32,266)	(35,716)
Less: Comprehensive (loss)/income attributable to redeemable noncontrolling interest	(309)	(23)	(584)	53
Comprehensive loss attributable to common stockholders	$ (14,064)	$ (11,482)	$ (31,682)	$ (35,769)